Advances in the application of claudins to tumor therapy.

Author: Siyuan CHEN ¹ ; Xue LIU ¹ ; Wenxin LUO ¹
Author Information

1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, Xiamen 361102, Fujian, China.
Publication Type:Journal Article
Keywords: Clostridium perfringens enterotoxin; antibody; claudin; targeted therapy; tumor
MeSH: Claudins; therapeutic use; Enterotoxins; Humans; Neoplasms; drug therapy; Tight Junctions
From: Chinese Journal of Biotechnology 2019;35(6):931-941
CountryChina
Language:Chinese
Abstract: Claudin proteins are the most crucial components of tight junctions, and play an essential role in maintaining cell polarity, regulating cell permeability and the intercellular ion. In recent years, many studies have shown that abnormality of claudins expression is implicated in the tumor progression. The expression correlates with tumor prognosis and can serve as a biomarker of prognosis and potential therapeutic targets. This review summarizes the current knowledge regarding claudin dysregulation in cancer and highlights the progress in claudin-based treatments.